Loading…
Clinically significant mutations in HIV-infected patients with lung adenocarcinoma
Background: Lung cancer is a major cause of death in HIV-infected (HIV+) persons. In this study, we compared the prevalence of tumour EGFR and KRAS mutations in a cohort of lung adenocarcinoma patients by HIV status. Methods: We collected data from 55 HIV+ patients with lung adenocarcinoma matched t...
Saved in:
Published in: | British journal of cancer 2017-10, Vol.117 (9), p.1392-1395 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background:
Lung cancer is a major cause of death in HIV-infected (HIV+) persons. In this study, we compared the prevalence of tumour
EGFR
and
KRAS
mutations in a cohort of lung adenocarcinoma patients by HIV status.
Methods:
We collected data from 55 HIV+ patients with lung adenocarcinoma matched to 136 uninfected comparators. We compared the prevalence of
EGFR
and
KRAS
mutations by HIV status. We then compared survival by HIV status and by cancer mutation status among HIV+ subjects.
Results:
Presence of
KRAS
and
EGFR
genetic alterations did not vary by HIV status (all
P
>0.1). There was no difference in overall survival by HIV status or by mutation status among HIV+ subjects.
Conclusions:
We found no major differences in the prevalence of
EGFR
or
KRAS
lung adenocarcinoma mutations by HIV status, suggesting that mutational testing should be conducted similarly regardless of the HIV status. |
---|---|
ISSN: | 0007-0920 1532-1827 |
DOI: | 10.1038/bjc.2017.333 |